Psoriasishttps://en.wikipedia.org/wiki/Psoriasis
Psoriasis is a chronic, non‑contagious autoimmune disease characterized by raised patches of abnormal skin. These patches are red, or purple in people with darker skin, and are dry, itchy, and scaly. Injury to the skin can trigger psoriatic changes at that site, a response known as the “Koebner phenomenon.”

Various treatments can help control the symptoms, including steroid creams, vitamin D₃ cream, ultraviolet light, and immunosuppressive drugs such as methotrexate. About 75 % of skin involvement improves with creams alone. Several biologic immunologic agents are currently being developed for the treatment of psoriasis.

Psoriasis is common, affecting 2–4 % of the population. Men and women are affected equally. The disease may begin at any age, but it typically starts in adulthood. Psoriatic arthritis occurs in up to 30 % of individuals with psoriasis.

○ Treatment ― OTC Drugs
Sunlight can help psoriasis because UV exposure induces immunologic changes in patients. A mild hydrocortisone ointment may help treat small psoriatic lesions.
#OTC steroid ointment

○ Treatment
Psoriasis is a chronic disease and a lot of treatment agents are being studied. Biologics are the most effective but very expensive.
#High potency steroid ointment
#Calcipotriol cream
#Phototherapy
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)
☆ AI Dermatology — Free Service
In the 2022 Stiftung Warentest results from Germany, consumer satisfaction with ModelDerm was only slightly lower than with paid telemedicine consultations.
  • Back and arms of a person with psoriasis
  • Typical psoriasis
  • Guttate Psoriasis; It often occurs after symptoms of a cold.
  • Guttate Psoriasis
  • A thick scaly plaque with erythema is a typical manifestation of psoriasis.
  • Psoriasis on the palms. If it occurs on the palms of the hands, blisters may form.
  • Severe 'pustular psoriasis'.
  • Guttate Psoriasis
References Psoriasis 28846344 
NIH
 Phototherapy 33085287 
NIH
 Tumor Necrosis Factor Inhibitors 29494032 
NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).